Internal Monitoring of Eye Movement in Schizophrenia

Schizophrenia Clinical Trial

Official title:

Internal Monitoring of Eye Movement in Schizophrenia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01011101
• Other study ID #: 100016
• Secondary ID: 10-EI-0016
• Status: Terminated
• Phase: N/A
• First received: November 10, 2009
• Last updated: October 5, 2017
• Start date: November 2, 2009
• Est. completion date: August 16, 2016

Study information

• Verified date: August 16, 2016
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background:

• Researchers are studying how humans are able to move our eyes to a remembered region even when the target has disappeared. The ability to do this suggests that the brain can keep track of where the eyes have looked, without an external target for continued reference. This is called corollary discharge.

• Other research has indicated that patients with schizophrenia might have difficulty monitoring their eye movements. The corollary discharge process may be defective in patients with schizophrenia, and perhaps delayed in time. Researchers have developed a test to examine this possibility in the hope of learning more about schizophrenia and eye movement.

Objectives:

• To assess whether there is a defect in internal monitoring of eye movements in patients with schizophrenia.

Eligibility:

• Individuals over 18 years of age who are able to give informed consent and are able to concentrate on a 20-minute task that involves following projected targets and moving their eyes to remembered locations.

• Individuals with schizophrenia will be recruited from an ongoing NIH protocol studying schizophrenia.

• In addition healthy will be recruited for this protocol.

Design:

• Researchers will check participants' vision in each eye, and ask them to sit at a machine that measures eye movement in order to complete research tasks. Researchers will monitor participants ability to complete these tasks.

• The first task involves simply following a target that jumps to different parts of the screen.

• The second is a 2-step task, in which a participant is asked to look at two separate light targets and then look at the remembered target positions when the lights are off.

• This protocol does not provide treatment. Participants will remain under the care of their own physicians during participation in this protocol.

Description:

OBJECTIVE:

To study if there is a defect in internal monitoring of eye movements in patients with schizophrenia.

STUDY POPULATION:

Patients with schizophrenia and normal controls.

DESIGN:

Patients and controls will be asked to follow targets to remembered locations and their eye movements will be monitored.

OUTCOME MEASURES:

Eye movements will be examined for evidence of internal monitoring (corollary discharge) defects which would result in mislocalizing remembered targets.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: August 16, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

• INCLUSION CRITERIA:

1. Adult subjects over 18 years of age who are able to give informed consent and are able to concentrate on a task for 20 minutes which involves following projected targets and moving their eyes to remembered locations.

EXCLUSION CRITERIA:<TAB>

1. Large refractive error requiring strong glasses. Glasses may interfere with the video eye movement recording system. However, participants may wear contact lenses. Subjects with a history of eye disease affecting vision or eye movements will also be excluded.

2. Participants with guardians will be excluded.

Related Conditions & MeSH terms

• Schizophrenia

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center, 9000 Rockville Pike	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Eye Institute (NEI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Andreasen NC, Nopoulos P, O'Leary DS, Miller DD, Wassink T, Flaum M. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol Psychiatry. 1999 Oct 1;46(7):908-20. Review. — View Citation

Campanella S, Guerit JM. How clinical neurophysiology may contribute to the understanding of a psychiatric disease such as schizophrenia. Neurophysiol Clin. 2009 Feb;39(1):31-9. doi: 10.1016/j.neucli.2008.12.002. Epub 2009 Jan 9. Review. — View Citation

Duhamel JR, Goldberg ME, Fitzgibbon EJ, Sirigu A, Grafman J. Saccadic dysmetria in a patient with a right frontoparietal lesion. The importance of corollary discharge for accurate spatial behaviour. Brain. 1992 Oct;115 ( Pt 5):1387-402. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of recordings between groups		End of study